Soleno Therapeutics Inc (NASDAQ:SLNO) shares, rose in value, with the stock price up by 1.98% to the previous day’s close as strong demand from buyers drove the stock to $81.91.
Actively observing the price movement in the recent trading, the stock is buoying the session at $80.32, falling within a range of $80.73 and $83.0. The value of beta (5-year monthly) is -2.672. Referring to stock’s 52-week performance, its high was $90.32, and the low was $41.50. On the whole, SLNO has fluctuated by 2.64% over the past month.
With the market capitalization of Soleno Therapeutics Inc currently standing at about $4.13 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-07.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SLNO’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of SLNO currently trading nearly -0.93% and 4.36% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.79, while the 7-day volatility ratio is showing 4.92% which for the 30-day chart, stands at 4.00%. Furthermore, Soleno Therapeutics Inc (SLNO)’s beta value is -2.56.
A comparison of Soleno Therapeutics Inc (SLNO) with its peers suggests the former has fared considerably weaker in the market. SLNO showed an intraday change of 1.98% in today’s session so far, and over the past year, it grew by 82.22%%.
Data on historical trading for Soleno Therapeutics Inc (NASDAQ:SLNO) indicates that the trading volumes over the past 10 days have averaged 1.62 and over the past 3 months, they’ve averaged 986.20K. According to company’s latest data on outstanding shares, there are 48.53 million shares outstanding.
Nearly 17.13% of Soleno Therapeutics Inc’s shares belong to company insiders and institutional investors own 94.56% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.06 million shares as on 2025-06-13, resulting in a short ratio of 6.19. According to the data, the short interest in Soleno Therapeutics Inc (SLNO) stood at 928.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 4.15 million. The stock has risen by 91.65% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLNO stock heading into the next quarter.
